This is a working overview of Angiotensin IV, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-24 and is reviewed periodically as new material appears.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Marketed for research use in some regions. |
| Human clinical data | Limited or absent | Most evidence is from cell and animal studies. |
| Primary proposed pathway | HGF/c-Met signaling | Angiotensin IV-related activity also reported. |
| Common study models | Rodent neurons and behavioral tasks | Results may not translate directly to humans. |
| Key uncertainty | Bioavailability and brain exposure | Questions remain about absorption and target engagement. |
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
== Biochemical structure == It is a low-molecular-weight neurotoxin which has highly functional polar groups: free phenolic OH and amine and guanidine residues. It also possesses arginine (free NH2) connected to a -NH (CH)3 NH (C ~) 3NH (CH) 5-NH- one through a peptide bond polyamine. The polyamine is connected to the asparagine's α-carboxyl group. The amino group of this aminoacid is linked to 2,4-dihydroxyphenyl acetic acid. Its structure was established using spectroscopy 1H, 13C-RMN, mass spectrometry, and elemental aminoacid analysis. A complete synthesis strategy of argiotoxin and derivatives was developed in order to make biological tests in different living beings. A noted type of argiotoxin, the Arg-636, which molecular formula is C29H52N10O6 [3], has a molecular weight of 636.78658 g/mol. It has a formal charge of 0. Its IUPAC name is: (2S) - N- { 5 - [ 3 - ( 3 - [ [ (2S)-2-amino-5-(diaminomethylideneamino) pentanoyl ] amino ] propylamino ) propylamino ] pentyl } -2- { [ 2 - (2,4-dihydroxyphenyl) acetyl ] amino } butanediamide
==== False information and fines ==== During the elections, Jornal da Band released false polling that showed Melo in the lead against d'Ávila. Melo's campaign would later post their findings onto his Instagram account. Jornal da Band would later correct the polling data and Melo's campaign removed the post from social media. He was later condemned by electoral courts under the Brazilian Election Justice and was made to pay 106,000 reais for spreading false information. The judge that made the decision made the call to forward the case to the Federal Police for a criminal investigation. Melo and Gomes were fined again through the Election Justice for 41,900 reais for a series of irregularities in the campaign's finances, including the use of provisions to print religiously styled pamphlets that displayed him appearing alongside city council candidates from the PTB, a party that had not formally become a member of his coalition. Allies of Melo also went around the city to spread rumors that if d'Ávila was elected, that she would close the city's churches and force people to eat dog meat.
=== Implementation === On May 10, 1977, Oklahoma became the first U.S. state to approve lethal injection when Governor David Boren signed a bill into law. Episcopal Reverend Bill Wiseman had introduced it into the Oklahoma legislature, where it passed and was quickly sent to the Governor's desk (Title 22, Section 1014(A)). The next day, Texas became the second U.S. state to approve a lethal injection law. Since then, until 2004, 37 of the 38 states using capital punishment introduced lethal injection statutes (the last state, Nebraska, maintained electrocution as its sole method until adopting injection in 2009, after its Supreme Court deemed the electric chair unconstitutional). On May 11, 1977, the day after the new method had become state law, Oklahoma's state medical examiner, Jay Chapman, proposed a new, less painful method of execution known as Chapman's protocol: "An intravenous (IV) saline drip shall be started in the prisoner's arm, into which shall be introduced a lethal injection consisting of an ultrashort-acting barbiturate in combination with a chemical paralytic." The Chapman protocol was approved by anesthesiologist Stanley Deutsch, formerly Head of the Department of Anesthesiology of the University of Oklahoma College of Medicine. On August 29, 1977, Texas adopted the new method of execution, switching from electrocution. On December 7, 1982, Texas became the first U.S. state or territory in the world to use lethal injection to carry out capital punishment, for the execution of Charles Brooks, Jr.
Sources: en.wikipedia.org
=== Specialized reactions === As with all carbonyl compounds, the protons on the α-carbon are labile due to keto–enol tautomerization. Thus, the α-carbon is easily halogenated in the Hell–Volhard–Zelinsky halogenation. The Schmidt reaction converts carboxylic acids to amines. Carboxylic acids are decarboxylated in the Hunsdiecker reaction. The Dakin–West reaction converts an amino acid to the corresponding amino ketone. In the Barbier–Wieland degradation, a carboxylic acid on an aliphatic chain having a simple methylene bridge at the alpha position can have the chain shortened by one carbon. The inverse procedure is the Arndt–Eistert synthesis, where an acid is converted into acyl halide, which is then reacted with diazomethane to give one additional methylene in the aliphatic chain. Many acids undergo oxidative decarboxylation. Enzymes that catalyze these reactions are known as carboxylases (EC 6.4.1) and decarboxylases (EC 4.1.1). Carboxylic acids are reduced to aldehydes via the ester and DIBAL, via the acid chloride in the Rosenmund reduction and via the thioester in the Fukuyama reduction. In ketonic decarboxylation carboxylic acids are converted to ketones. Organolithium reagents (>2 equiv) react with carboxylic acids to give a dilithium 1,1-diolate, a stable tetrahedral intermediate which decomposes to give a ketone upon acidic workup. The Kolbe electrolysis is an electrolytic, decarboxylative dimerization reaction. It gets rid of the carboxyl groups of two acid molecules, and joins the remaining fragments together.
The nitrogen–phosphorus detector (NPD) is also known as thermionic specific detector (TSD) is a detector commonly used with gas chromatography, in which thermal energy is used to ionize an analyte. It is a type of flame thermionic detector (FTD), the other being the alkali flame-ionization detector (AFID also known as AFD). With this method, nitrogen and phosphorus can be selectively detected with a sensitivity that is 104 times greater than that for carbon.
Having "engaged in practices that exposed players to significant risks to their health and safety as well as the risk of using substances that were prohibited by the AFL Anti-Doping Code and the World Anti-Doping Code". Allowing "a culture of frequent, uninformed and unregulated use of the injection of supplements" at the club. Had "failed to meaningfully inform players of the substances the subject of the program and obtain their informed consent to the administration of the substances". Having an incomplete record-keeping system made it impossible to determine with certainty whether or not players had been administered banned supplements. The bypassing of human resources practices relating specifically to the employment of Robinson and Dank. The interim report found that Essendon had intended the program to be an innovative program of unprecedented scale to deliver a competitive edge to the club, but that it had not done adequate research nor established clear lines of accountability for those implementing the program. The AFL Tribunal later commented that there was a "deplorable absence of records in the program relating to its administration." Essendon and the AFL discussed and negotiated penalties for the charges over two days in August. On 27 August 2013, five days before the final round of the 2013 home-and-away season, the following penalties were agreed to and imposed:
=== Magnetic resonance imaging === Magnetic resonance imaging (MRI) is a non-invasive imaging technique that uses strong magnetic fields and radiofrequency pulses to generate detailed anatomical and functional images of the body. MRI provides excellent soft tissue contrast and is widely used in theranostics for its ability to visualize anatomical structures and assess physiological processes. In theranostics, MRI allows for the detection and characterization of tumors, assessment of tumor extent, and evaluation of treatment response. MRI can provide information on tissue perfusion, diffusion, and metabolism, aiding in the selection of appropriate therapies and monitoring their effectiveness. Advancements in MRI technology have expanded its capabilities in theranostics. Techniques such as functional MRI (fMRI) enable the assessment of brain activation and connectivity, while diffusion-weighted imaging (DWI) provides insights into tissue microstructure. The development of molecular imaging agents, such as superparamagnetic iron oxide nanoparticles, allows for targeted imaging and tracking of specific molecular entities.
Sources: en.wikipedia.org
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.
Preclinical research has focused on synaptic growth, cognitive performance in animals, and HGF/c-Met signaling. These are experimental findings, not established treatments.
Legality varies by country and intended use. It is commonly sold as a research chemical, and sales for human consumption may be restricted. Local regulations should be checked.
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.